Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8+ T-Cell Peptide Epitope of Vaccinia and Variola Viruses

ABSTRACT CD8+ T lymphocytes have been shown to be involved in controlling poxvirus infection, but no protective cytotoxic T-lymphocyte (CTL) epitopes are defined for variola virus, the causative agent of smallpox, or for vaccinia virus. Of several peptides in vaccinia virus predicted to bind HLA-A2.1, three, VETFsm(498-506), A26L(6-14), and HRP2(74-82), were found to bind HLA-A2.1. Splenocytes from HLA-A2.1 transgenic mice immunized with vaccinia virus responded only to HRP2(74-82) at 1 week and to all three epitopes by ex vivo enzyme-linked immunosorbent spot (ELISPOT) assay at 4 weeks postimmunization. To determine if these epitopes could elicit a protective CD8+ T-cell response, we challenged peptide-immunized HLA-A2.1 transgenic mice intranasally with a lethal dose of the WR strain of vaccinia virus. HRP2(74-82) peptide-immunized mice recovered from infection, while naïve mice died. Depletion of CD8+ T cells eliminated protection. Protection of HHD-2 mice, lacking mouse class I major histocompatibility complex molecules, implicates CTLs restricted by human HLA-A2.1 as mediators of protection. These results suggest that HRP2(74-82), which is shared between vaccinia and variola viruses, may be a CD8+ T-cell epitope of vaccinia virus that will provide cross-protection against smallpox in HLA-A2.1-positive individuals, representing almost half the population.

[1]  M. Larkin.  Monkeypox spreads as US public-health system plays catch-up , 2003, The Lancet. Infectious diseases.

[2]  Todd M. Allen,et al.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques , 2001, Nature Medicine.

[3]  V. M. Tarabrina.  [On complications in smallpox vaccination]. , 1961, Sovetskaia meditsina.

[4]  S. Hansen,et al.  Duration of antiviral immunity after smallpox vaccination , 2003, Nature Medicine.

[5]  J. Berzofsky,et al.  Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections , 1999, Immunological reviews.

[6]  S. H. van der Burg,et al.  Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes , 1993, European journal of immunology.

[7]  J D Millar,et al.  Complications of smallpox vaccination, 1968. , 1969, The New England journal of medicine.

[8]  J. Berzofsky,et al.  Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. , 2003, The Journal of infectious diseases.

[9]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.

[10]  G. Karupiah,et al.  Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication , 1995, Journal of virology.

[11]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[12]  I. M. Belyakov,et al.  The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. , 1998, The Journal of clinical investigation.

[13]  K. Parker,et al.  Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. , 1992, Journal of immunology.

[14]  J. Berzofsky,et al.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Rodella,et al.  Differential production of IFN-gamma, analyzed at the single-cell level, by specific subsets of human NK and T cells from healthy and HIV(+) subjects. , 2000, Cytometry.

[16]  S. Goebel,et al.  Vaccinia virus host range genes. , 1990, Virology.

[17]  M. Enserink.  U.S. Monkeypox Outbreak Traced to Wisconsin Pet Dealer , 2003, Science.

[18]  U. Koszinowski,et al.  Lysis mediated by T cells and restricted by H-2 antigen of target cells infected with vaccinia virus , 1975, Nature.

[19]  Hans Hengartner,et al.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice , 1994, Nature.

[20]  B. Moss,et al.  Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. , 1995, Developments in biological standardization.

[21]  T. Monath,et al.  Development of a novel vaccinia-neutralization assay based on reporter-gene expression. , 2003, The Journal of infectious diseases.

[22]  R. Blanden,et al.  Cell‐mediated cytotoxicity against ectromelia virus‐infected target cells. I. Specificity and kinetics , 1974, European journal of immunology.

[23]  M. Perkus,et al.  NYVAC: a highly attenuated strain of vaccinia virus. , 1992, Virology.

[24]  I. M. Belyakov,et al.  Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. , 2003, Current molecular medicine.

[25]  D. Spehner,et al.  Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. , 1993, The Journal of general virology.

[26]  H. Stickl,et al.  The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. , 1978 .

[27]  M. Merchlinsky,et al.  Developing new smallpox vaccines. , 2001, Emerging infectious diseases.

[28]  J. Berzofsky,et al.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. , 2004, The Journal of clinical investigation.

[29]  J. Berzofsky,et al.  Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion , 2001, European journal of immunology.

[30]  J. Berzofsky,et al.  High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. , 2001, The Journal of clinical investigation.

[31]  B. Moss,et al.  Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. , 1988, Virology.

[32]  B. Moss,et al.  Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  F. Ennis,et al.  Clonal vaccinia virus grown in cell culture as a new smallpox vaccine , 2003, Nature Medicine.

[34]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[35]  J. Schlom,et al.  Agonist peptide from a cytotoxic t‐lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1‐type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide , 2000, International journal of cancer.

[36]  V. Engelhard,et al.  Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. , 1996, Journal of immunology.

[37]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[38]  J. Stephenson.  Monkeypox outbreak a reminder of emerging infections vulnerabilities. , 2003, JAMA.

[39]  J. Millar,et al.  [Complications of smallpox vaccination]. , 2010, [Hokenfu zasshi] The Japanese journal for public health nurse.

[40]  S. Goebel,et al.  The complete DNA sequence of vaccinia virus. , 1990, Virology.

[41]  John Cruz,et al.  Quantitation of CD8+ T Cell Responses to Newly Identified HLA-A*0201–restricted T Cell Epitopes Conserved Among Vaccinia and Variola (Smallpox) Viruses , 2003, The Journal of experimental medicine.

[42]  A. Vitiello,et al.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.

[43]  P. Cresswell,et al.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids , 2004, Immunogenetics.

[44]  I. M. Belyakov,et al.  Strategies for designing and optimizing new generation vaccines , 2001, Nature Reviews Immunology.

[45]  J. Berzofsky,et al.  Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. , 2001, International immunology.

[46]  F. Lemonnier,et al.  HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice , 1997, The Journal of experimental medicine.

[47]  U. Koszinowski,et al.  Target cell‐dependent T cell‐mediated lysis of vaccinia virus‐infected cells , 1975, European journal of immunology.

[48]  J. Berzofsky,et al.  Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. , 1997, Journal of immunology.

[49]  U. Kees,et al.  A single genetic element in H-2K affects mouse T-cell antiviral function in poxvirus infection , 1976, The Journal of experimental medicine.

[50]  I. M. Belyakov,et al.  Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. , 2004, Immunity.

[51]  V. Engelhard,et al.  Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen , 2000, The Journal of experimental medicine.

[52]  T. Waldmann,et al.  Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  F. Falkner,et al.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.

[54]  Anthony S. Fauci,et al.  Bioterrorism: A clear and present danger , 2001, Nature Medicine.

[55]  Hans-Georg Rammensee,et al.  Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Berzofsky,et al.  Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  H. Stickl,et al.  [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, Betriebshygiene, praventive Medizin.

[58]  J. Berzofsky,et al.  Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Frelinger,et al.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Berzofsky,et al.  Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. , 1998, The Journal of clinical investigation.

[61]  Robert DeMars,et al.  Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter , 1991, Nature.

[62]  A. Ureta-Vidal,et al.  Design of a polyepitope construct for the induction of HLA‐A0201‐restricted HIV 1‐specific CTL responses using HLA‐A*0201 transgenic, H‐2 class I KO mice , 2001, European journal of immunology.

[63]  J. Berzofsky,et al.  Epitope-Enhanced Conserved HIV-1 Peptide Protects HLA-A2-Transgenic Mice Against Virus Expressing HIV-1 Antigen , 2003, The Journal of Immunology.